Literature DB >> 28474168

Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.

Qiang Xu1, Zuofu Zhang2, Weixue Sun2, Baiqiang Hu2.   

Abstract

The purpose of the study was to investigate the association of single-nucleotide polymorphisms (SNPs) within excision repair cross-complementation (ERCC) gene polymorphisms, additional gene-gene interaction, and haplotype combination with osteosarcoma risk. Generalized multifactor dimensionality reduction (GMDR) was used to screen the best interaction combination among SNPs. Logistic regression was performed to investigate the association between six SNPs within ERCC gene, additional gene-gene interaction on osteosarcoma risk. Haplotype analysis was performed using SNPstats ( http://bioinfo.iconcologia.net/SNPstats ). Osteosarcoma risk was significantly higher in carriers with the T allele of ERCC2-rs1799793 than those with GG genotype (GT+ TT vs. GG), adjusted OR (95% CI) = 1.56 (1.13-2.01), and higher in carriers with the A allele of ERCC3-rs4150441 than those with GG genotype (GA+ AA vs. GG), adjusted OR (95% CI) = 1.63 (1.25-2.09). GMDR model indicated a significant two-locus model (p = 0.0107) involving rs1799793 and rs4150441; cross-validation consistency of the two-locus model was 9/10; and the testing accuracy was 60.11%. Participants rs1799793-GT or -TT and rs4150441-GA or -AA genotype have the highest osteosarcoma risk, compared to subjects with rs1799793-GG and rs4150441-GG genotype, OR (95% CI) = 2.87 (1.21-4.63), after covariates adjustment. Haplotype containing the rs1799793-T and rs11615-T alleles was associated with a statistically increased osteosarcoma risk, OR (95% CI) = 1.47 (1.12-1.92). We found that the T allele of ERCC2-rs1799793 and the A allele of ERCC3-rs4150441, interaction between rs1799793 and rs4150441, and haplotype containing the rs1799793T and rs11615-T alleles were all associated with increased osteosarcoma risk.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28474168     DOI: 10.1007/s00335-017-9693-8

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  20 in total

1.  Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Chao Cao; Yan-mei Zhang; Ran Wang; Shi-fang Sun; Zhong-bo Chen; Hong-ying Ma; Yi-ming Yu; Qun-li Ding; Li-hua Shu; Zai-chun Deng
Journal:  Chin Med J (Engl)       Date:  2011-07       Impact factor: 2.628

2.  Association between angiogenic growth factor genetic polymorphisms and the risk of osteosarcoma.

Authors:  H F Zhang; J P Yan; Y S Zhuang; G Q Han
Journal:  Genet Mol Res       Date:  2015-09-08

3.  Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.

Authors:  D Caronia; A Patiño-García; R L Milne; M Zalacain-Díez; G Pita; M R Alonso; L T Moreno; L Sierrasesumaga-Ariznabarreta; J Benítez; A González-Neira
Journal:  Pharmacogenomics J       Date:  2009-05-12       Impact factor: 3.550

4.  Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.

Authors:  Ting Hao; Wei Feng; Jie Zhang; Yong-Jian Sun; Gang Wang
Journal:  Asian Pac J Cancer Prev       Date:  2012

5.  Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma.

Authors:  X Ma; Y Zhang; T S Sun; J H Yao
Journal:  Genet Mol Res       Date:  2016-03-31

6.  Contribution of the GSTP1 gene polymorphism to the development of osteosarcoma in a Chinese population.

Authors:  W R Qu; J Wu; R Li
Journal:  Genet Mol Res       Date:  2016-08-05

7.  [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].

Authors:  Keiichiro Ishibashi; Norimichi Okada; Yusuke Tajima; Toru Ishiguro; Kouki Kuwabara; Tomonori Ohsawa; Kensuke Kumamoto; Yoshitaka Tsuji; Norihiro Haga; Takeo Iwama; Hideyuki Ishida; Tsuneko Onouchi; Koji Yakabi
Journal:  Gan To Kagaku Ryoho       Date:  2011-11

8.  Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer.

Authors:  Sun Kyung Baek; Si-Young Kim; Jae Jin Lee; Yoon Wha Kim; Hwi Joong Yoon; Kyung Sam Cho
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

9.  Participation of BER and NER pathways in the repair of DNA lesions induced at low N-nitrosodiethylamine concentrations.

Authors:  Claudia Alessandra Fortes Aiub; José Luiz Mazzei; Luis Felipe Ribeiro Pinto; Israel Felzenszwalb
Journal:  Toxicol Lett       Date:  2004-12-01       Impact factor: 4.372

10.  The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development.

Authors:  Kamel Rouissi; Islem Ben Bahria; Karim Bougatef; Raja Marrakchi; Nejla Stambouli; Khouloud Hamdi; Mohamed Cherif; Mohamed Riadh Ben Slama; Mohamed Sfaxi; Fethi Ben Othman; Mohamed Chebil; Amel Benammar Elgaaied; Slah Ouerhani
Journal:  BMC Cancer       Date:  2011-03-22       Impact factor: 4.430

View more
  2 in total

1.  Overexpression of ERCC3 is associated with poor prognosis in patients with pancreatic cancer.

Authors:  Shujie Wang; Wenjing Liu; Yueli Ni; Lifeng Wang; Yuzhi Zhu; Qiong Shi; Zihan Yi; Wenjie Wang; Lili Liu; Lijuan Yang; Yingmin Kuang; Yuechun Zhu; Qiao Zhang; Zhe Yang
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

2.  Epidemiological Evidence for Associations Between Genetic Variants and Osteosarcoma Susceptibility: A Meta-Analysis.

Authors:  Dechao Yuan; Jie Tian; Xiang Fang; Yan Xiong; Nishant Banskota; Fuguo Kuang; Wenli Zhang; Hong Duan
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.